Lys552
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Ubiquitylation Site Page: > Lys552  -  HIPK2 (human)

Site Information
FQNMEICkRRVNMyD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3059902

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 3 ) , mass spectrometry ( 1 , 2 ) , mutation of modification site ( 3 ) , western blotting ( 3 )
Disease tissue studied:
lung cancer ( 3 ) , non-small cell lung cancer ( 3 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on HIPK2:
protein degradation ( 3 )

References 

1

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

2

Udeshi ND, et al. (2013) Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics 12, 825-31
23266961   Curated Info

3

Winter M, et al. (2008) Control of HIPK2 stability by ubiquitin ligase Siah-1 and checkpoint kinases ATM and ATR. Nat Cell Biol 10, 812-24
18536714   Curated Info